Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Antengene Corporation Limited
  6. News
  7. Summary
    6996   KYG039571008

ANTENGENE CORPORATION LIMITED

(6996)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Antengene Corporation Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021

09/23/2021 | 06:49pm EDT

Antengene Corporation Limited reported Unaudited consolidated earnings results for the Six months ended June 30, 2021. Loss was RMB 232,995,000 compared to RMB 537,747,000 a year ago. Basic loss per share Attributable to Ordinary Equity Holders of the Parent was RMB 0.37 compared to RMB 2.58 a year ago.


© S&P Capital IQ 2021
All news about ANTENGENE CORPORATION LIMITED
10/15Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inh..
CI
10/05Antengene Corporation Limited commences an Equity Buyback Plan for 67,118,064 shares, r..
CI
10/03CORRECTION : Antengene to Repurchase Up to Nearly $13 Million Shares; Shares Rise 3%
MT
10/03ANTENGENE : to Repurchase Up to $5.1 Million Shares
MT
09/23Antengene Corporation Limited Reports Unaudited Consolidated Earnings Results for the S..
CI
09/15Antengene Selected as a Constituent of the FTSE Global Equity Index Series
DJ
09/03ANTENGENE : Cancer Treatment Gets Approval for Phase 1 Clinical Trial in Australia; Shares..
MT
08/23ANTENGENE : Gets Chinese Regulator Nod for Phase 2 Trial of Potential Myelofibrosis Treatm..
MT
08/23ANTENGENE : Announces Approval of the Phase II Study of Selinexor for the Treatment of Mye..
PR
08/23Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for..
CI
More news
Financials
Sales 2021 2,00 M 0,31 M 0,31 M
Net income 2021 -752 M -118 M -118 M
Net cash 2021 3 307 M 517 M 517 M
P/E ratio 2021 -7,43x
Yield 2021 -
Capitalization 5 815 M 909 M 909 M
EV / Sales 2021 1 254x
EV / Sales 2022 18,7x
Nbr of Employees 219
Free-Float 65,3%
Chart ANTENGENE CORPORATION LIMITED
Duration : Period :
Antengene Corporation Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTENGENE CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,67 CNY
Average target price 22,02 CNY
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Jian Ming Mei Chairman & Chief Executive Officer
Donald Andrew Lung Chief Financial Officer & Executive Director
Bo Shan Chief Scientific Officer
Kevin Lynch Executive Director & Chief Medical Officer
Yiteng Liu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ANTENGENE CORPORATION LIMITED-38.51%909
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121